Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
Date:10/23/2007

d synthetase (AS)), and a pre-prodrug of phenylacetate (PAA).

About Urea Cycle Disorder

A urea cycle disorder is an inherited, inborn error of metabolism present in an estimated 1 in 10,000 live births in the U.S. Patients with UCDs lack or are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. The age of onset of UCDs is typically in the neonatal period, but onset can occur at any age, depending on the severity of the disorder. Left untreated, UCDs can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

There is no cure for UCDs. Adherence to a low-protein diet is a key component to chronic disease management. Current therapies include arginine supplementation, which drives functional parts of the urea cycle, essential amino acid supplementation, replacement of urea cycle intermediates, and administration of nitrogen-scavenging drugs including BUPHENYL(R) for chronic management and AMMONUL(R) (sodium phenylacetate and sodium benzoate) disease Injection 10%/10% for episodes of acute hyperammonemia. Orthotopic liver transplantation may also be considered for patients with severe disease.

About Hyperion Therapeutics

Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in gastrointestinal (GI) and hepatology therapeutic programs and products that address underserved patient populations or unmet medical needs. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: http://www.hyperiontx.com.

About AMMONUL(R)

AMMONUL(R) is indicated as adjunctive therapy for the treatment
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Emeryville, Calif., Aug. 18 Adamas Pharmaceuticals, Inc., ... entered into a Cooperative Research and Development Agreement (CRADA) ... preclinical studies evaluating Adamas, triple combination antiviral drug (TCAD) ... TCAD therapy includes Adamas, investigational proprietary fixed-dose oral combination ...
... Aug. 17 Stereotactic body radiotherapy (SBRT) is a highly effective ... new research from The University of Texas in Houston, according to ... Miami and Palm Beach. , ( www.cyberkni f ... "This data confirms the established method of cancer treatment used ...
Cached Medicine Technology:Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain 2Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain 3New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors 2
(Date:4/23/2014)... Fruits and vegetables are often displayed in the ... are also plenty of high-sugar foods. A new ... food is portrayed in children,s TV programmes as ... viewing, dietary habits and weight status. , Steingerdur ... food in the popular Swedish children,s TV show ...
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... scientists have found a way to block abnormal cholesterol ... atherosclerosis, the main cause of heart attacks and strokes ... condition develops when fat builds inside blood vessels over ... reducing their ability to feed oxygen-rich blood to the ... of experiments, described April 7 in the journal ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... DIEGO, Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: ... an investigational new,drug (IND) application to the U.S. ... an internally developed, orally-bioavailable, small,molecule inhibitor of the ... Phase I clinical trials of SGX523 for solid ...
... Germany and OXFORD, England, December 3 /PRNewswire-FirstCall/,-- Evotec ... it has,completed the sale of its Chemical Development ... GBP 31.5 million (approx. EUR 44 million),effective November ... focus even more on its strategy to,become an ...
... donation" appeal at last,night,s Hutch Holiday Gala helped push ... Fred Hutchinson Cancer Research Center., The annual black-tie ... event took place from 5 p.m. until midnight at ... portion of the live auction during which every,dollar donated ...
... at bay, expert says , SUNDAY, Dec. 2 (HealthDay News) -- ... all too easy to pack on extra pounds when joining family ... help you avoid weight gain, says Jennifer Ebelhar, an assistant professor ... to indulge in a little of your favorite holiday treats. But ...
... hours, work at night, struggle to remain awake at work, ... drowsy driving episode, according to a study published in the ... authored by Linda D. Scott, PhD, of Grand Valley State ... collected from 895 full-time hospital staff nurses, who completed logbooks ...
... 1 issue of the journal SLEEP is the first to ... duration are associated with an elevated risk of mortality by ... Jane E. Ferrie, PhD, of the University College London Medical ... and 55 years of age. Baseline screening (Phase 1), ...
Cached Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 2Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 3Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 4Health News:32nd Annual Hutch Holiday Gala Raises Millions for Cancer Research 2Health News:32nd Annual Hutch Holiday Gala Raises Millions for Cancer Research 3Health News:Holidays Don't Have to Leave You Heavier 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4Health News:Short, long sleep duration associated with increased mortality 2
... The NEW Vibratome 3000 Deluxe Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... The Vibratome comes standard with ... These specimen blocks are utilized for ... Vibratome holding vice. The blocks ... viewing and can be reused. ...
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
... specifically for the Vibratome, this sapphire microtomy ... time to cut thin Vibratome sections with ... thick (1 micron) plastic sections. The ... Vibratome 1000 of a thickness in the ...
Medicine Products: